JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
adult patients with essential tremor (ET) did not meet its primary endpoint. Suvecaltamide is a highly selective and state-dependent modulator of T-type calcium channels, which play a role in the brain's control of muscle movement. Per the data readout from the phase IIb study (NCT05122650), treatment with suvecaltamide 30mg failed to achieve statistical significance on the primary endpoint of change from baseline to week 12 on the Essential Tremor Rating Assessment Scale (TETRAS) modified composite outcome score compared with placebo. TETRAS is a validated clinical scale designed specifically for the assessment of ET severity. The study also failed to achieve statistical significance on the key secondary endpoint of the Clinical Global Impression-Severity scale, which is a measure of the severity of illness compared with placebo at week 12. However, treatment with suvecaltamide 30mg demonstrated numeric improvements on the primary endpoint and key secondary endpoint of the
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals' essential tremor drug falls flat in Phase IIb trial [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at Needham & Company LLC from $222.00 to $210.00. They now have a "buy" rating on the stock.MarketBeat
- Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential TremorPR Newswire
- Innovative Developments in Acute Lymphocytic Leukemia (ALL) Treatments Global Pipeline Report 2024 [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 5/1/24 - Miss
JAZZ
Sec Filings
- 6/14/24 - Form ARS
- 6/14/24 - Form DEFA14A
- 6/14/24 - Form DEF
- JAZZ's page on the SEC website